Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavapadon - Cerevel Therapeutics

Next Previous
Drug Profile

Tavapadon - Cerevel Therapeutics

Alternative Names: CVL 751; PF 6649751; PF-06649751

Latest Information Update: 04 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Parkinson's disease

Most Recent Events

  • 01 Dec 2025 Cerevel Therapeutics completes a phase III TEMPO-4 trial in Parkinson Disease (In adults, In elderly in the US, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Serbia, Spain, and Ukraine (PO) (NCT04760769)
  • 28 Nov 2025 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO, Tablet)
  • 26 Sep 2025 Preregistration for Parkinson's disease (Early-stage disease, In the elderly, In adults) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top